EMA Authorised: Prialt (ziconotide) — Esteve Pharmaceuticals GmbH

View source ↗

Summary

EMA authorised Prialt (ziconotide) for intrathecal use to treat pain, with Esteve Pharmaceuticals GmbH as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• Prialt (ziconotide)

Snippet

Status: Authorised. Therapeutic area: Injections, Spinal;Pain. MAH: Esteve Pharmaceuticals GmbH. Decision date: 14/04/2026